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ABSTRACT
Background
Psychosis is a severe mental condition that is characterized by a loss of contact with reality
and is typically associated with hallucinations and delusional beliefs. There are numerous
psychiatric conditions that present with psychotic symptoms, most importantly schizophrenia,
bipolar affective disorder, and some forms of severe depression referred to as psychotic
depression. The pathological mechanisms resulting in psychotic symptoms are not understood,
nor is it understood whether the various psychotic illnesses are the result of similar biochemical
disturbances. The identification of biological markers (so-called biomarkers) of psychosis is a
fundamental step towards a better understanding of the pathogenesis of psychosis and holds
the potential for more objective testing methods.
Methods and Findings
Surface-enhanced laser desorption ionization mass spectrometry was employed to profile
proteins and peptides in a total of 179 cerebrospinal fluid samples (58 schizophrenia patients,
16 patients with depression, five patients with obsessive-compulsive disorder, ten patients with
Alzheimer disease, and 90 controls). Our results show a highly significant differential
distribution of samples from healthy volunteers away from drug-naı ¨ve patients with first-
onset paranoid schizophrenia. The key alterations were the up-regulation of a 40-amino acid
VGF-derived peptide, the down-regulation of transthyretin at ;4 kDa, and a peptide cluster at
;6,800–7,300 Da (which is likely to be influenced by the doubly charged ions of the
transthyretin protein cluster). These schizophrenia-specific protein/peptide changes were
replicated in an independent sample set. Both experiments achieved a specificity of 95% and a
sensitivity of 80% or 88% in the initial study and in a subsequent validation study, respectively.
Conclusions
Our results suggest that the application of modern proteomics techniques, particularly mass
spectrometric approaches, holds the potential to advance the understanding of the
biochemical basis of psychiatric disorders and may in turn allow for the development of
diagnostics and improved therapeutics. Further studies are required to validate the clinical
effectiveness and disease specificity of the identified biomarkers.
The Editors’ Summary of this article follows the references.
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Schizophrenia is the most devastating and enduring
psychotic disorder affecting as many as 1% of the population
worldwide, with a similar prevalence between the sexes and
throughout diverse cultures and geographic areas [1,2]. To
date, the etiology of schizophrenia remains elusive. The
disorder is almost certainly the result of a complex
interaction between numerous predisposing genes and
environmental factors. Many studies have focused on the
identiﬁcation of schizophrenia ‘‘risk genes’’/genetic poly-
morphisms, and although such ‘‘risk genes’’ may play a role in
a small number of schizophrenia cases, the great majority of
patients do not exhibit any apparent polymorphisms [3]. An
alternative approach to genetic studies is to screen for disease
markers (biomarkers). Biomarkers or biomarker signatures
are indicators of a disease state that are usually linked to an
ongoing pathophysiology and thus may also provide infor-
mation and insights into the underlying molecular mecha-
nisms of a given disease. Typical examples include diabetes
and cardiovascular disorders, where increased glucose and
low-density lipoprotein levels, respectively, are hallmark
biomarkers for the diseases. Both cardiovascular disorders
and diabetes (particularly Type II diabetes) are very similar to
schizophrenia in that they are a result of genetic and
environmental factors. Thus, even if the etiologies for
schizophrenia and other psychotic disorders remain un-
known, a biomarker or biomarker signature that accurately
identiﬁes the clinical syndrome would allow for improved
diagnosis, prognosis, and disease monitoring as well as the
development of novel therapeutic approaches.
Surface-enhanced laser desorption ionization (SELDI) mass
spectrometry is a powerful tool for identifying a character-
istic ‘‘ﬁngerprint’’ of proteins and peptides in body ﬂuids and
tissues for a given condition, e.g., drug treatments and
diseases (for review, see [4]). This technology utilizes modiﬁed
surfaces to capture proteins/peptides, while a time-of-ﬂight
mass spectrometer is used to quantitate and measure the
molecular weights of compounds ranging from small mole-
cules and peptides of less than 1,000 Da up to proteins of 500
kDa. Quantiﬁable differences in protein/peptide patterns can
be statistically evaluated using automated computer pro-
grams that represent each protein/peptide measured in the
bioﬂuid as a coordinate in multi-dimensional space. This
approach has been most successful in the ﬁeld of clinical
biomarker discovery (for example, see [5–7]) as it can be used
as a diagnostic tool without needing to know the biomarker’s
identity. The SELDI system also has the capability to run
hundreds of samples in a single experiment. In addition, all
the signals from SELDI mass spectrometry are derived from
native proteins/peptides (unlike some other proteomics
technologies requiring protease digestion), thus directly
reﬂecting the underling physiology of a given condition.
In this study, we undertook an extensive protein/peptide–
proﬁling analysis of cerebrospinal ﬂuid (CSF), investigating a
total of 179 CSF samples (90 controls, 58 ﬁrst-onset, drug-
naı ¨ve schizophrenia patients, 16 depression patients, ﬁve
patients with obsessive-compulsive disorder [OCD], and ten
patients with Alzheimer disease) using SELDI mass spectrom-
etry in combination with computerized pattern-recognition
analysis. We found highly signiﬁcant and reproducible
differences in samples obtained from ﬁrst-onset, drug-naı ¨ve
patients with a diagnosis of paranoid schizophrenia as
compared to age-matched controls. However, as no samples
from patients with non-schizophrenia psychosis were in-
cluded in the analysis (with the exception of three samples
from patients with psychotic depression), no clear conclu-
sions can be drawn with regards to the schizophrenia-
speciﬁcity of the biomarkers as compared to a ﬁrst-onset
psychosis signature.
Materials and Methods
Clinical Samples
The Ethical Committee of the Medical Faculty of the
University of Cologne reviewed and approved the protocol of
this study and the procedures for sample collection and
analysis. All study participants gave their written informed
consent. All clinical investigations were conducted according
to the principles expressed in the Declaration of Helsinki.
CSF and serum samples were collected from drug-naı ¨ve
patients diagnosed with ﬁrst-episode paranoid schizophrenia
Table 1. Demographic Details of Subjects in the First CSF SELDI Experiment
Demographic Variable Healthy Volunteers First-Onset, Drug-Naı ¨ve Schizophrenia Patients
Age (y)
a 28.3 6 7.0 28.7 6 9.2
Gender (male/female) 24/16 30/11
Ethnicity (Caucasian) 95.0% 98.0%
Smoking
b 32.5% (62.5%) 61.0% (9.8%)
Alcohol
c 0% (97.5%) 4.9% (24.3%)
Cannabis
d 50.0% (45.0%) 51.2% (41.5%)
Cannabis (urine test)
e 0% (75.0%) 14.6% (63.4%)
Other drugs
f 7.5% (87.5%) 21.9% (68.3%)
Note that demographic data of some patients are not available or tests did not perform at the time so that the sum may not be 100%.
aData are shown as average 6 standard deviation.
bData are shown as percentage of smokers (percentage of non-smokers).
cData are shown as percentage of subjects with alcohol abuse and addiction (percentage of subjects with low/occasional consumption of alcohol).
dData are shown as percentage of subjects with history of cannabis use (percentage of subjects with no history of cannabis use).
eData are shown as percentage of subjects tested as cannabis-positive on urine drug screen (percentage of subjects with cannabis-negative urine screen).
fData are shown as percentage of subjects with history of consuming hallucinogens, stimulants, entactogens, opioids, sedatives, and volatile solvents (percentage of subjects with no
history).
doi:10.1371/journal.pmed.0030428.t001
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295.30 [n¼54] or 298.8 [n¼4], total n¼58), from 16 patients
diagnosed with major depressive disorder (DSM-IV 296.22–4;
296.33–4), from ﬁve patients with OCD (DSM-IV 300.3), and
from demographically matched healthy volunteers (n ¼ 80)
(Tables 1 and 2). Fresh-frozen prefrontal cortex tissue
(Brodmann area 9) from gray matter of eight schizophrenia
and eight well-matched control individuals was obtained
from the Neuropathology Consortium of the Stanley Brain
Collection (Stanley Medical Research Institute, http://www.
stanleyresearch.org). A detailed history of antipsychotic drug
use of included patients is listed in Tables S1 and S2.
Preparation of CSF Samples for SELDI Analysis
An amount (5 ll) of each CSF sample was applied to
protein chips with different chemical properties at various
pH conditions. The best condition was chosen at pH 9.0 on
strong anion exchanger Q10 chips, based on number and
separation of peaks resolved. Brieﬂy, the array spots were
pre-activated twice with binding buffer (100 mM Tris-HCl
[pH 9.0]) at room temperature for 10 min on a shaker
(frequency ¼ 600 rpm). An amount (5 ll) of binding buffer
was added to each spot prior to the addition of 5 ll of CSF
sample. The protein chips were incubated on a shaker for 60
min at room temperature, then washed twice with binding
buffer and once with H2O, and air-dried. The chips were then
sequentially treated twice with 0.6 ll of a 100% saturated
sinapinic acid (3,5-dimethoxy-4-hydroxycinnamic acid) in
50% acetonitrile and 0.5% triﬂuoroacetic acid. The chips
were analyzed with the Ciphergen ProteinChip Reader
(Ciphergen ProteinChip System Series 4000, Ciphergen
Biosystems, http://www.ciphergen.com). Each sample was
analyzed twice to conﬁrm reproducibility in identifying the
differentially expressed proteins and to ensure stability of
instrument performance.
SELDI–Time-of-Flight Mass Spectrometer Analysis
The arrays were analyzed with the Ciphergen ProteinChip
System Series 4000 (Ciphergen Biosystems). Mass spectra of
proteins were generated by using an average of 254 laser
shots at a laser intensity of 1,800 arbitrary units. For data
acquisition, the detection size ranged between 2.5 and 200
kDa. The laser was focused at 10 kDa. The mass-to-charge
ratio (m/z) of each of the proteins captured on the array
surface was determined relative to external calibration
standards (Ciphergen Biosystems): bovine insulin (5,733.6
Da), human ubiquitin (8,564.8 Da), bovine cytochrome c
(12,230.9 Da), bovine superoxide dismutase (15,591.4 Da),
horseradish peroxidase (43,240 Da), and BSA (66,410 Da). The
data were analyzed with ProteinChip data analysis software
version 3.0 and Ciphergen Express Software 3.0 (Ciphergen
Biosystems). Matrix attenuation was set at 2,500 Da, and shot
sequence was set with one warming shot at 2,000 nJ followed
by four shots at 1,800 nJ. The Ciphergen Express Software 3.0
was used to compile all spectra and to autodetect quantiﬁed
mass peaks within a mass range of between 2,500 and 200,000
Da, and the signal-to-noise threshold was set at 5. Peak
labeling was completed using second-pass peak selection with
0.2% of the mass window, and estimated peaks were added.
The peak information of all spectra was exported for further
statistical analysis.
Peptide and Protein Identification
Typically, 10-ll CSF samples from both the control and
schizophrenia groups were applied to Q10 protein chips at
pH 9.0 (50 mM Tris-HCl). Proteins/peptides bound to the chip
were eluted with 5 ll of elution buffer (30% acetonitrile, 50
mM sodium acetate [pH 3.0]) and desalted using a C18 Ziptip
(Millipore, Billerica, Massachusetts, United States) according
to the manufacturer’s instructions. The peptides were eluted
with 0.1% formic acid/50% aqueous acetonitrile (2 ll) and
were further examined by MALDI mass spectrometry for the
conﬁrmation of the enriched 3,959-Da peak in the CSF
sample of the patients with schizophrenia. A CSF sample with
a high 3.959 peptide level was also loaded onto a C18 nano-
column for online LC-ESI-MS/MS on a QSTAR quadrupole-
TOF mass spectrometer (Applied Biosystems, Foster City,
California, United States) for de novo sequencing.
For identiﬁcation of protein biomarkers, CSF proteins
were puriﬁed from pooled CSF by a combination of anion
exchange chromatography (HyperD, Ciphergen Biosystems)
followed by SDS-PAGE. CSF protein (;1 mg) was diluted in
two volumes of buffer (50 mM Tris-HCl [pH 9]) and applied
Table 2. Demographic Details of Subjects in the CSF Validation Sample Set
x Healthy Volunteers First-Onset, Drug-Naı ¨ve Schizophrenia Patients Patients with Depression (Treated)
Age (y)
a 27.3 6 3.8 27.6 6 7.9 46.6 617.4
Gender (male/female) 20/20 10/7 8/8
Ethnicity (Caucasian) 95.0% 100% 100%
Smoking
b 52.5% (45.0%) 58.8% (11.8%) 37.5% (18.8%)
Alcohol
c 0% (85.0%) 5.8% (41.1%) 25% (43.8%)
Cannabis
d 70% (20%) 58.8% (41.2%) 37.5% (18.8%)
Cannabis (urine test)
e 0% (77.5%) 23.5% (64.7%) 12.5% (56.3%)
Other drugs
f 22.5% (65%) 23.5% (76.5%) 12.5% (87.5%)
Note that for some patients, demographic data are not available as tests were not performed at the time of sample collection. Thus, the data given above may not add up to 100%.
aData are shown as average 6 standard deviation.
bData are shown as percentage of smokers (percentage of non-smokers).
cData are shown as percentage of subjects with alcohol abuse and addiction (percentage of subjects with low/occasional consumption of alcohol).
dData are shown as percentage of subjects with history of cannabis use (percentage of subjects with no history of cannabis use).
eData are shown as percentage of subjects tested as cannabis-positive on urine drug screen (percentage of subjects with cannabis-negative urine screen).
fData are shown as percentage of subjects with history of consuming hallucinogens, stimulants, entactogens, opioids, sedatives, and volatile solvents (percentage of subjects with no
history).
doi:10.1371/journal.pmed.0030428.t002
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bound protein was then eluted by step gradients using pH 7.0,
6.0, 5.0, 4.0, and 3.0 buffers (Expression Difference Mapping
Kit, Ciphergen Biosystems). The fractions were concentrated
using Centricon YM10 (Millipore) to ;20 ll, followed by SDS-
PAGE analysis (NuPAGE Bis-Tris gel, 4%–12%, Invitrogen,
Carlsbad, California, United States). The band expected to
correspond to the SELDI peak was cut from the gel.
Approximately one third of the excised gel band was used
for passive elution of the protein followed by SELDI analysis
to conﬁrm that the correct protein had been isolated. The
remaining two thirds of the gel band was in-gel digested with
trypsin (1:50; Promega, Madison, Wisconsin, United States)
overnight at room temperature. The resulting peptide
mixtures were then analyzed by LC-ESI-MS/MS (QSTAR,
Applied Biosystems), and the protein was identiﬁed by
database searching using Mascot software (Matrix Science,
London, United Kingdom).
S-cysteinylated or S-glutathionylated isoforms of proteins
were conﬁrmed by comparing the spectra before and after
on-chip reduction using b-mecaptoethanol. In brief, CSF
protein and peptide binding was performed as described
above and, in the ﬁnal step, each spot was washed with 100 ll
of 1 mM HEPES [pH 7.5]. The proteins and peptides on the
chips were then reduced with 1/40 b-mecaptoethanol (1 ll)
for 30 min at room temperature. Water (1 ml) was added onto
each spot and evaporated. This procedure was repeated twice.
Matrix was then added, and data were acquired using
ProteinChip Reader (Ciphergen ProteinChip System Series
4000).
Quantitative analysis of transthyretin in human serum
samples was carried out by enzyme-linked immunosorbent
assay (ELISA). Samples were defrosted from 80 8C and mixed
on a benchtop vortexer for 10 min before experimental work
commenced. All samples were assayed blind to the clinical
conditions. The identities of all subjects were kept blind by
code numbers until all biochemical analyses had been
completed.
Controls and patient-derived human serum samples were
diluted 1,000 times with PBS (pH 7.4) (Sigma, St. Louis,
Missouri, United States), and 100 ll of each diluted sample
was loaded onto ELISA Maxisorb plates (Nunc, http://www.
nuncbrand.com) together with transthyretin standards (Sig-
ma) before being incubated for 1 h. All samples were tested in
duplicate. After washing with washing buffer (0.03% Tween
20 in PBS), the plates were blocked with 100 llo f5 %
skimmed-milk powder for 60 min. Transthyretin antibody
(100 ll) (DakoCytomation, Glostrup, Denmark, 1:500 diluted
Figure 1. Protein/Peptide Profiling of CSF Samples from First-Onset, Drug-Naı ¨ve Schizophrenia Patients Using SELDI Mass Spectrometry
(A) Typical CSF protein/peptide spectrum using an anion exchanger chip (Q10; 50 mM Tris-HCl [pH 9.0]) showing the m/z range of 2,500–15,000 from a
healthy volunteer is shown.
(B) The peak intensity of protein/peptide peaks from SELDI spectra were analyzed using PCA and PLS-DA models. A 3D PLS-DA scores plot indicates
clusters of healthy volunteers (in blue) and untreated, drug-naı ¨ve schizophrenia patients (in red).
(C) and (D) PLS-DA scores and loadings plots. The scores plot is similar to (B) but only the first two components were used to discriminate between
healthy controls and patients. The loading plot as shown in (D) indicates the key protein/peptide peaks contributing the most towards the separation as
shown in (C). The 3,959-Da VGF23–62 peptide was found to predominantly contribute to the separation between the two groups.
doi:10.1371/journal.pmed.0030428.g001
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plates for 60 min. The plates were washed four times with
washing buffer followed by the addition of 100 llo f
secondary antibody (anti-rabbit HPP-linked IgG [Cell Signal-
ing Technology, Beverly, Massachusetts, United States]
1:2000) to each well and incubated for 60 min. After washing
with washing buffer three times, 100 ll of substrate (TMB
One solution, Promega) was added into each well, and the
mixture was incubated at room temperature for 10 min. The
plate was read at 450 nm (Model 680, Bio-Rad, Hercules,
California, United States).
Western Blot Analysis
The preparation of human brain samples for Western blot
analysis and the details of performing Western blotting were
as described previously [8]. In brief, equivalent amounts of
protein (30 lg per sample) were resolved by electrophoresis
on 10% polyacrylamide gels and transferred onto nitro-
cellulose, which was then incubated with primary antibody
(anti-transthyretin [DakoCytomation] 1:1,000) or anti-VGF
(Santa Cruz Biotechnology [Santa Cruz, California, United
States] 1:500) in 3% milk–PBS overnight at 4 8C, followed by
incubation of a secondary antibody (HRP-conjugated anti-
rabbit secondary antibody [Cell Signaling Technology,
1:2500]) at room temperature for 1 h. Enhanced chemilumi-
nescence (LumiGlu, Cell Signaling Technology) was used to
detect signals from the blot. Consistency of protein loading
and transfer was determined by Ponseau S staining.
Statistical Analysis
Multivariate statistical analysis techniques including prin-
cipal component analysis (PCA), partial least-squares dis-
criminate analysis (PLS-DA), and partial least-squares (PLS)
were employed to summarize the data output from Cipher-
gen Express. Holdout cross-validation was performed three
times so that the sensitivity and speciﬁcity of the PLS model
could be estimated. In each of the three rounds of holdout
cross-validation, one third of the samples were randomly
selected to form the validation data and the remaining
samples were used as the training data. All multivariate
analyses were performed using SIMCA-Pþ 10 (Umetrics,
http://www.umetrics.com). Sensitivity is deﬁned as the pro-
portion of true positives that it detects of all the positives,
and speciﬁcity is deﬁned as the proportion of true negatives
that it detects of all the negatives. Where appropriate, a t-test
was performed using the Statistical Package for Social
Scientists (SPSS/PCþ; SPSS, Chicago, Illinois, United States).
Correlation analysis was performed using Matlab 7.0.1
(Mathwork, Natick, Massachusetts, United States). Two-way
analysis of variance (ANOVA) was performed using the
‘‘ANOVA’’ function from the CAR package in R (R project,
http://cran.r-project.org). Type III sums of squares was used as
this study had an unbalanced experimental design.
Results
Alterations of CSF Protein/Peptide Profiles in First-Onset,
Drug-Naı ¨ve, Paranoid Schizophrenia Patients
In a ﬁrst set of experiments, we examined protein/peptide
proﬁles of CSF samples from 41 ﬁrst-onset, drug-naı ¨ve,
paranoid schizophrenia patients and 40 demographically
matched healthy volunteers using SELDI mass spectrometry.
CSF proteins and peptides were proﬁled using Q10 (strong
anion exchanger) chips at pH 9.0. An example of the CSF
protein/peptide proﬁle of a healthy volunteer is shown in
Figure 1A. Approximately 75 peaks can be readily detected
with a signal-to-noise ratio of .5 under this binding
condition. Plots of PLS-DA scores based on SELDI spectra
of CSF samples showed a clear differentiation between
healthy volunteers and drug-naı ¨ve patients with ﬁrst-onset,
paranoid schizophrenia (Figure 1B and 1C). Similar results
were found using PCA (unpublished data). The loading
coefﬁcients indicated that the peak with an m/z of 3,959
contributed the most to the separation of the two groups
(Figure 1D).
Further analyses showed a 2.8-fold elevation of an m/z ¼
3,959 peptide in ﬁrst-onset, drug-naı ¨ve, paranoid schizophre-
nia patients as compared to the demographically matched
control group (p ¼ 10
 8, t-test; Figure 2). In addition, the
loading plot also showed signiﬁcant reductions in peaks of m/z
¼ 23,490 and clusters of peaks between m/z ¼ 13,600–14,000
and m/z¼6,800–7,300 (;20% decreases, p , 0.01, t-test), all of
which also contributed to the separation between classes. We
have identiﬁed the proteins and peptides at m/z¼3,959 and in
the cluster of m/z ¼ 13,600–14,000. The m/z ¼ 6,800–7,300
biomarkers are likely to be inﬂuenced by the doubly charged
ion signals of the m/z¼13,600–14,000 protein cluster and may
only reﬂect the altered levels in m/z ¼ 13,600–14,000 (Figure
S1). The sensitivity and speciﬁcity of this model based on
holdout cross validation was 80% and 95%, respectively
(Table 3; see Materials and Methods). These alterations were
not affected by most demographic variables including age,
gender, alcohol, and illicit drug use, although we identiﬁed a
correlation with smoking (Table S3). However, a disease-
associated increase in VGF levels remains signiﬁcant after
controlling for smoking effects using a two-way ANOVA
(Table S3.5).
Identification of the 3,959-Da Peptide as a VGF Fragment
The 3,959-Da peptide was puriﬁed using identical con-
ditions as employed in the proﬁling experiment followed by
C18-Ziptip puriﬁcation (see Figure S2). The eluted proteins
Table 3. Sensitivity and Specificity of PLS Models Calculated from the Two Independent Experiments
Experiment Samples (Healthy Volunteers/Patients with Schizophrenia) Sensitivity
a Specificity
b
Initial experiment (40/41) 80% 95%
Validation experiment (40/17) 88% 95%
aSensitivity is defined as the proportion of true positives that it detects of all the positives.
bSpecificity is defined as the proportion of true negatives that it detects of all the negatives.
doi:10.1371/journal.pmed.0030428.t003
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Demographic Variable Control Subjects Patients with Schizophrenia
Age (y)
a 45.3 6 6.8 40.0 6 11.0
Gender (male/female) 6/2 5/3
PMI 27.0 6 11.6 32.4 6 11.6
Storage (months)
b 55.6 6 5.4 69.5 6 7.0
pH 6.4 6 0.3 6.5 6 0.2
Fluphenazine mg equivalents N/A 60,000 6 64,200
aData are shown as average 6 standard deviation.
bData indicate the period for which the samples have been stored at  80 8C.
doi:10.1371/journal.pmed.0030428.t004
Figure 2. Up-Regulation of m/z ¼ 3,959 VGF23–62 Peptide Peak in CSF from First-Onset, Drug-Naı ¨ve Schizophrenia Patients
Forty healthy volunteers and 41 untreated paranoid schizophrenia CSF samples were included in this study. A clear up-regulation of the peak at 3,959
Da was observed (as shown in [A], with five representative spectra from each group). Figure 2B reveals the relative intensity of a 3,959-Da peak in
healthy volunteers and first-onset, drug-naı ¨ve schizophrenia patients. Figure 2C shows a Western blot analysis of VGF protein in the prefrontal cortex of
age-matched controls and patients with schizophrenia. Eight schizophrenia and eight control brains (prefrontal cortex, age matched) were randomly
selected, and Western analysis was performed using a polyclonal antibody against the C-terminal region of the VGF protein. VGF was found up-
regulated in four patients with schizophrenia (out of eight patients), while no signal was detected in the control patients. This experiment was repeated
twice on the same samples under identical conditions, except that a different batch antibody from the same company was used. Similar results were
obtained. For demographic details, see Table 4.
doi:10.1371/journal.pmed.0030428.g002
PLoS Medicine | www.plosmedicine.org November 2006 | Volume 3 | Issue 11 | e428 2150
Biomarkers for First-Onset Psychosisand peptides from Ziptips were subjected to MALDI to
conﬁrm the mass, and the peak was identiﬁed as a 40-amino
acid peptide using de novo sequencing (Figure S2). This
peptide sequence was mapped to amino acids 23–62 of the
native VGF protein (in bold underlined, Figure 3A), a
neurosecretory protein known to regulate metabolism [9]
and synaptic plasticity [10], and is immediately next to a
predicted secretory signal peptide. Interestingly, another
VGF-derived peptide with an m/z of 3,690 in CSF that did
not appear to differ between control and schizophrenia
patients was identiﬁed (p ¼ 0.85, t-test). This peptide showed
the same peptide sequence as the 40-amino acid VGF peptide
except that three amino acids were absent at the ﬁrst N-
terminal (Figure 3B; de novo sequencing data not shown). This
indicates that the 40-amino acid VGF peptide with the ‘‘APP’’
sequence in the amino terminus may have speciﬁc functions
and/or may be linked to the pathophysiology of schizophrenia.
Increased VGF Protein Expression in Post-Mortem Brain
Tissue from Patients with Schizophrenia
To examine whether VGF protein expression is also altered
in schizophrenic post-mortem brain tissue, we performed
Western blot analysis on gray matter in prefrontal cortex
tissue from eight patients with schizophrenia and eight
demographically matched control subjects. Western blot
analysis using an antibody recognizing the C-terminal
sequences of VGF showed a strong expression in four out
of eight patients while, in control brains, the level of VGF was
below the detection level (Figure 2C).
Identification of the 13.6–14-kDa Protein Cluster as
Transthyretin
The protein cluster between 13.6 and 14.1 kDa contains
four peaks (Figure 4A and 4B), three of which were
consistently down-regulated in CSF from ﬁrst-onset, drug-
naı ¨ve schizophrenia patients (p , 0.01; Figure 4B, lower
panel). Studies have suggested that these peaks may be from
S-cysteinylated derivatives of transthyretin protein [11,12], a
thyroid hormone–binding protein that transports thyroxine
from the bloodstream to the brain. On-chip reduction of CSF
peptide/protein performed using b-mercaptoethanol at room
temperature showed that the three peaks m/z¼13,741, 13,875,
and 13,923 were reduced to a single peak (Figure 4C),
conﬁrming that they are derived from the same protein. To
determine the protein’s identity, a pair of CSF samples from a
healthy volunteer and a patient with schizophrenia were
applied to an anion exchanger column (HyperD, Ciphergen
Biosystems) and eluted with pH 9–pH 3 buffers. A major band
(;13–15 kDa) was eluted in the pH 3 fraction (Figure 4D, left
panel). The band was conﬁrmed to be the peak cluster at
around 13.6–14 kDa in the SELDI spectrum by eluting the
protein from the band and running on an NP20 chip to
match the mass (Figure 4E). This protein was then digested
with trypsin and sequenced using LC-MS/MS. The protein was
identiﬁed as transthyretin (Figure 4D, right panel).
Down-Regulation of Transthyretin in Serum Samples from
the Same Subjects as well as Prefrontal Cortex Tissue from
Patients with Schizophrenia
It has been estimated that 3% of transthyretin in the
ventricular CSF and 10% of the transthyretin in lumbar CSF
are derived from blood [13]. To evaluate the contribution of
blood transthyretin to the changes found in CSF in patients
with schizophrenia, we also investigated serum transthyretin
levels taken from the same individuals (at the same time as the
CSF was collected) on whom we had reported in this study
(for demographics, see Tables 1 and 2) using ELISA. We found
a moderate, but signiﬁcant, decrease in transthyretin levels in
sera from patients with schizophrenia compared to controls
Figure 3. Mapping and Identification of the Biomarker Peptide Derived from the Native VGF Protein
The 3,959-Da ‘‘schizophrenia’’ peptide was mapped to amino acids 23–62 of the native VGF protein (in bold; underlined), immediately next to a
predicted secretory signal peptide (using InterProScan: www.ebi.ac.uk/ cgi-bin/iprscan).
Another native VGF-derived peptide did not show differential expression between healthy volunteers and patients with schizophrenia (as shown in
Figure 2A). This peptide has an identical sequence except that it is three amino acids shorter at the N-terminus compared to the ‘‘disease-specific’’ VGF
peptide.
doi:10.1371/journal.pmed.0030428.g003
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Biomarkers for First-Onset Psychosis(15% decrease, p ¼ 0.0007, t-test) (Figure 5A). However, we
found no correlation between CSF and serum transthyretin
from the same individuals, suggesting that the transthyretin
level is regulated independently in CSF and serum (Figure
5B). Interestingly, we found an ;40% down-regulation of
transthyretin levels in post-mortem prefrontal cortex from
patients with schizophrenia compared with controls using
Western blot (Figure 5C).
Validation of Protein/Peptide Biomarkers in an
Independent Sample Set
We validated our biomarker model in Figure 1 using an
independent sample set comprising a further 17 ﬁrst-onset,
drug-naı ¨ve schizophrenia patients and 40 demographically
matched healthy volunteers. These samples were run using
identical conditions as in the previously described experi-
ment. PLS-DA scores and loadings plots showed a very similar
Figure 4. Down-Regulation of Three Different Forms of Transthyretin in CSF from First-Onset, Drug-Naı ¨ve Schizophrenia Patients
Examples of CSF spectra from healthy volunteers and patients with schizophrenia within 6–17 kDa are shown in (A). The peak cluster indicated (red
cursor) is enlarged in (B). Statistical details of each sub-peak are listed in the table presented just below (B). On-chip reduction of CSF peptide/protein
with b-mecaptoethanol at room temperature showed that the three peaks 13,741, 13,875, and 13,923 Da were reduced into a single peak (C),
suggesting that they are different S-cysteinylated derivatives of the same protein. To identify the protein, CSF samples from a healthy volunteer and a
patient with schizophrenia were applied to an anion exchanger column (HyperD, Ciphergen Biosystems) and eluted with pH 9–pH 3 buffers. A major
;14–15-kDa band was eluted in the pH 3 fraction (D, left panel). The protein was identified as transthyretin using LC-MS/MS (D, right panel) and the
sequence coverage is shown in red. Note, that all the peptides shown have an E-score of , 0.05, indicating a high probability for the assigned protein
identity. In addition, the band was confirmed to be the peak cluster at around 13.5–14 kDa in the spectra by eluting the protein(s) from the gel and
SELDI analysis (E).
doi:10.1371/journal.pmed.0030428.g004
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Biomarkers for First-Onset Psychosisresult as found in Figure 1 with predominant changes in m/z¼
3,959, the cluster of 6,800–7,300-Da peptides (likely inﬂu-
enced by the doubly charged ions from transthyretin
proteins), and the cluster of 13,600–14,000 proteins (Figure
6). This suggests that these identiﬁed alterations in CSF
proteins and peptides are a consistent ﬁnding and thus may
reﬂect genuinely the early pathophysiology of schizophrenia.
The sensitivity and speciﬁcity of this model were 88% and
95%, respectively (Table 3). As with the results from the ﬁrst
study, we did not ﬁnd an inﬂuence of most demographic
variables on these alterations, with the exception of a
potential effect of cannabis use (urine-positive drug screen)
on CSF transthyretin levels (p ¼ 0.08; Table S3). However, as
for the smoking effect, disease-associated changes in trans-
thyretin levels remain signiﬁcant after controlling for
cannabis use using a two-way ANOVA (Table S3.6–S3.8).
Disease Specificity of the Schizophrenia Biomarker Panel
As many psychiatric disorders and neurological diseases
share similar symptoms with schizophrenia, it is crucial to test
the disease speciﬁcity of these protein/peptide biomarkers.
We therefore examined CSF samples of three additional
psychiatric/neurological disorders, namely depression, OCD,
and Alzheimer disease. CSF samples from 16 patients with
depression and ﬁve patients with OCD, together with CSF
samples from 40 healthy volunteers, were analyzed with
SELDI-MS using the condition described previously. We
found a partial separation between controls and patients with
depression (Figure 7A); the key variables contributing to the
separation were the above-mentioned VGF23–62 peptide and
a secretogranin II peptide 529–566 (Figure 7B; sequencing
data not shown). No difference was found between controls
and the ﬁve patients with OCD (unpublished data). These
Figure 5. Transthyretin Levels in Sera of First-Onset, Drug-Naı ¨ve Schizophrenia Patients and Prefrontal Cortex Post-Mortem Tissue from Schizophrenia
Patients
The serum samples from the same patients whose CSF protein profiles were measured in Figures 1 and 6 were included in this study. Figure 5A shows
serum tranythyretin levels in patients with schizophrenia significantly decreased by ;15% compared to control subjects. Data are shown in mean 6
standard deviation, and the asterisk denotes p¼0.0007 (t-test). Figure 5B indicates no correlation between serum transthyretin and CSF SELDI signals
from one of the transthyretin isoforms (m/z ¼ 13,741) in the second sample set (for demographics, see Table 2). Similar results were found when
comparing with signals from other isoforms in CSF (unpublished data). Figure 5C shows an ;40% decrease of transthyretin expression in prefrontal
cortex of five patients with schizophrenia and in five control subjects. For demographic details, see Table 5.
doi:10.1371/journal.pmed.0030428.g005
Table 5. Demographic Details of Subjects Investigated for Transthyretin Expression by Western Blot Analysis of Post-Mortem Brain
Demographic Variable Control Subjects Patients with Schizophrenia
Age (y)
a 46.2 6 6.0 44.8 6 8.8
Gender (male/female) 4/1 3/2
PMI 26.6 6 7.9 26.8 6 16.9
Storage (months)
b 55.2 6 5.2 69.6 6 10.0
pH 6.4 6 0.3 6.3 6 0.2
Fluphenazine mg equivalents N/A 70,000 6 70,200
aData are shown as average 6 standard deviation.
bData indicate the period for which the samples have been stored at  80 8C.
doi:10.1371/journal.pmed.0030428.t005
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Biomarkers for First-Onset Psychosisresults indicate that the VGF peptide alone may not be a
speciﬁc marker for a given psychiatric disease (possibly due to
overlapping disease processes, which are not least implied by
the fact that patients with a family history of affective
disorder have an increased risk for developing schizophrenia,
and vice versa). Our data thus suggest that disease speciﬁcity
may be achieved with a panel of biomarkers (Table S4).
As three out of 16 depression patients presented with
psychotic symptoms, we analyzed the psychotic and non-
psychotic subgroups separately to examine whether the
identiﬁed biomarkers are speciﬁc for schizophrenia or
merely for acute psychosis. No differences could be observed
between these two subgroups, and the psychotic subgroup did
not co-cluster with schizophrenia patients, suggesting that
VGF23–62 and transthyretin peptide/protein changes are
biomarkers for schizophrenia rather than acute psychosis
(Figure S3). However, as the sample size of patients with
psychotic depression was very small, the speciﬁcity of the
biomarker signature will need to be conﬁrmed on a larger set
of samples from patients with psychotic depression, bipolar
affective psychosis, and other neuropsychiatric illnesses that
present with psychotic states.
In addition, we also analyzed CSF samples from ten
patients with Alzheimer disease and from ten age-matched
and sex-matched controls using identical experimental
conditions. No signiﬁcant differences between the two groups
were identiﬁed, although some clear alterations were found
using other experimental conditions (unpublished data).
Discussion
Initial analysis of SELDI spectra of a total of 81 CSF
samples (41 from patients with schizophrenia, and 40 from
controls) showed a differential distribution of samples from
drug-naı ¨ve patients with ﬁrst-onset paranoid schizophrenia
away from healthy volunteer samples (Figure 1B–1D). The
protein/peptide proﬁle of CSF was found to be characteristi-
cally altered in paranoid schizophrenia patients, with the key
alterations being the prominent up-regulation of a 40-amino
acid VGF peptide and the down-regulation of transthyretin at
;14 kDa along with a peptide cluster at ;6,800–7,300 Da that
appeared co-regulated with the transthyretin cluster. These
schizophrenia-speciﬁc protein/peptide changes were repli-
cated/validated in an independent sample set (n ¼ 58) using
identical conditions (Figure 6). Both experiments achieved an
astonishingly high speciﬁcity (rate of true negative) of 95%
and a sensitivity of 80% or 88% in the initial study and in the
subsequent validation study, respectively (Table 3). This
means that virtually no control samples clustered with the
s c h i z o p h r e n i ag r o u p( F i g u r e1 Ba n d1 C ) .F o rah i g h
diagnostic validity and consequent therapeutic interventions,
an accurate identiﬁcation of those individuals who truly have
the disease is most critical. Correlation analyses suggest that
these key alterations are not due to sex, gender, alcohol,
smoking, or illicit drug use.
We also investigated the disease speciﬁcity of this bio-
marker panel with a smaller number of CSF samples from
patients with depression (including three patients with acute
psychotic depression), OCD, and Alzheimer disease. Interest-
ingly, depression and schizophrenia share an increase in the
VGF23–62 peptide expression, while transthyretin protein
levels were not found to be signiﬁcantly altered in depression
(although we observed a trend towards down-regulation).
Indeed, depression samples were most prominently charac-
terized by a distinct decrease of a secretogranin II 529–566
peptide. No difference was found between controls and OCD
patients (unpublished data). Additionally, we did not ﬁnd any
signiﬁcant difference between control and Alzheimer disease
CSF samples regarding the schizophrenia biomarker panel
(unpublished data).
One of the key ﬁndings of this study is the up-regulation
of a 40-amino acid VGF23–62 peptide in CSF of ﬁrst-onset,
drug-naı ¨ve schizophrenia patients and, to a lesser degree, in
patients with depression (Figure 7). Interestingly, a 3.69-kDa
Figure 6. PLS-DA Analysis of CSF Protein/Peptide Profiles from an Independent Validation Sample Set Containing 17 First-Onset, Drug-Naı ¨ve
Schizophrenia Patients and 40 Healthy Volunteers
The demographic details of this sample set are listed in Table 2. The PLS-DA scores plot shows a separation between patients (in red) and healthy
volunteers (in blue). The loadings plot indicates similar key variables (e.g., the 3,959-Da VGF23–62 peptide [in red] and transthyretin protein signals
between 13,600 and 14,000 [in blue]) identified in the first experiment (see Figure 1).
doi:10.1371/journal.pmed.0030428.g006
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Biomarkers for First-Onset PsychosisVGF26–62 peptide with an identical sequence to the
VGF23–62 peptide, except for the absence of the ﬁrst three
amino acids at the amino terminus, did not appear to be
differentially expressed in CSF from schizophrenia or
depression patients compared to healthy volunteers. How-
ever, this VGF26–62 peptide was reported to be decreased
in frontotemporal dementia [11]. In addition, a down-
regulation of a peptide of 4.82 kDa corresponding to a
further VGF peptide (containing amino acids 378–398) was
found to be changing in amyotrophic lateral sclerosis [14]
and Alzheimer disease [15], highlighting the importance of
t h i sp r o t e i ni nn e u r o l o g i c a l / psychiatric disorders. The
identiﬁed 40-amino acid VGF23–62 peptide may have a
distinct function in the schizophrenia/depression disease
process, may reﬂect a disease-associated protease/peptidase
dysfunction, and/or may imply the presence of pathological
processes in neurons since VGF is selectively expressed in
neurons in brain, particularly in the hypothalamus (for
review see [16,17]). At this point in time, the biological
function of this 40-amino acid VGF23–62 peptide is
unknown; however, the full-length protein has been linked
to synaptic plasticity [10] as well as penile erection through
the activation of paraventricular oxytocinergic neurons [18],
and the circadian clock [19]. Future studies are required to
explore the possible functions of this and other disease-
associated VGF peptides and their respective peptidases.
The increased level of the 40-amino acid VGF peptide may
indicate an increase of native (full-length) VGF protein and/
or the processing of the protein in the brain. In addition, our
data showed that VGF expression was increased in half of the
schizophrenia post-mortem brains (Figure 2C). As post-
mortem samples were collected from chronic patients who
had been chronically treated with antipsychotic drugs, we
cannot exclude the possibility of medication effects. How-
ever, in view of our CSF results from drug-naı ¨ve schizophre-
nia patients (Figure 1), it is likely that the observed changes in
VGF protein/peptide expression are a disease-related phe-
nomenon. Studies have shown that VGF is a secreted
polypeptide that is selectively expressed by neurons and by
several endocrine and neuroendocrine tissues (for review
[16,17]), and is transported in dense core vesicles with the
VGF-derived processed peptides being released via a regu-
lated secretory pathway [16,17]. Knockout of the VGF gene in
mice generated a lean, hypermetabolic, hyperactive pheno-
type, demonstrating that VGF may regulate energy balance
[9]. The observation of an increase of the VGF peptide in CSF
from patients with schizophrenia, therefore, may point to a
hypometabolic state in the schizophrenia brain. Whether or
not this is linked to ‘‘hypofrontality’’, a consistent ﬁnding
showing decreased metabolic activity in the prefrontal cortex
during cognitive activation in patients with schizophrenia
[20,21], requires further examination.
Our ‘‘metabonomics’’ data derived from the identical
samples used in the current study indicates that there is an
increase of CSF glucose level in ﬁrst-onset, drug-naı ¨ve
schizophrenia patients which was not observed in sera [22].
This further suggests that the schizophrenia brain may be in a
hyperglycemic state, possibly linked to deﬁciencies in glucose
metabolism since we found the majority of glycolysis enzymes
down-regulated in prefrontal cortex in a study on post-
mortem schizophrenia brain [23]. Interestingly, knockout of
the VGF gene increases insulin sensitivity in animal models
[24], suggesting that an increase of VGF may theoretically
decrease insulin sensitivity in the brain. This may explain the
increase in glucose levels in CSF from ﬁrst-onset, drug-naı ¨ve
schizophrenia patients.
In this study, we also observed a moderate, but consistent,
decrease in the transthyretin proteins in CSF from ﬁrst-onset
schizophrenia patients. Transthyretin is a thyroid hormone–
binding protein that transports thyroxine from the blood-
stream to the brain [25]. This protein is expressed at a high
rate in the brain choroid plexus, from which it is released into
the CSF [25]. In peripheral tissues, it is expressed primarily in
liver [13]. Only an estimated 3% of transthyretin in the
ventricular CSF and an estimated 10% of the transthyretin in
lumbar CSF are derived from blood [13]. Our ELISA results
Figure 7. CSF Proteomic Profiles of Depression Patients
CSF samples from 16 patients with depression (green triangles), together with 40 healthy volunteers (blue dots), were analyzed with SELDI-MS using
Q10 anion exchanger protein chips at pH 9 (50 mM Tris-HCl).
(A) The scores plot shows a partial separation between controls and patients with schizophrenia.
(B) The loading plot indicates VGF23–62 and a depression-specific secretogranin II 529–566 peptide to be the key protein/peptide peaks contributing
the most towards the group separation.
doi:10.1371/journal.pmed.0030428.g007
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whose CSF were investigated in this study showed that there is
an ;15% decrease of transthyretin levels in serum (p¼0.0007,
t-test; Figure 5A). However, there was no correlation between
the level of serum transthyretin and SELDI signals from CSF
transthyretin, suggesting that liver-derived tranthyretin may
not contribute to the down-regulation in CSF (Figure 5B).
Experiments perfusing isolated sheep brains showed that all
newly synthesized transthyretin was secreted from the
choroid plexus towards the ventricles. The synthesis of this
protein is required for the transport of thyroxine [26]. Thus,
the reduced level of transthyretin in CSF suggests a lower
thyroxine transport in brains of patients with schizophrenia.
Indeed, our result showing a down-regulation in transthyretin
protein in the post-mortem brain tissue from patients with
schizophrenia (Figure 5C) further supports this notion
It is noteworthy that thyroid dysfunction is relatively
common in patients with schizophrenia [27,28], and indeed
with other psychiatric disorders [29], possibly genetically
linked to the disorders. In addition, in patients with severe
forms of both hypo- and hyper-thyroidism, psychotic
symptoms may occur, and the clinical picture frequently
resembles that of schizophrenia [30], which may imply that an
increase in central nervous system thyroxine function may be
linked. Interestingly, long-term administration of clozapine
has been shown to induce transthyretin expression in rat
hippocampus and cerebral cortex [31], implying that cloza-
pine enhances central nervous system thyroxine function,
supporting the clinical relevance of transthyretin in the early
pathophysiology of schizophrenia. Transthyretin has also
been found to be differentially expressed in CSF of several
other neurological and psychiatric diseases. Sullivan et al.
found a 9.6% down-regulation of transthyretin levels (p ¼
0.05, t-test) in CSF from patients with [32]. This is in keeping
with our observation of a trend towards down-regulation of
transthyretin signals (Figure 7A). In frontotemporal demen-
tia, Hansson et al. observed increased expression of two
isoforms of transthyretin in CSF using 2D electrophoresis.
Taken together, our results stress the importance of trans-
thyretin in the pathophysiology of psychiatric and neuro-
logical diseases.
In summary, our results suggest that the application of
modern proteomics techniques, particularly mass spectro-
metric approaches, holds the potential to advance the
understanding of the biochemical basis of psychiatric
disorders and may in turn allow for the development of
diagnostics and better therapeutics. Further studies are
required to validate the clinical utility and disease speciﬁcity
of the identiﬁed biomarkers.
Limitations and Clinical Potential of the Findings
One of the key limitations of the present study is that no
(or very few) samples from patients with non-schizophrenia
psychosis were investigated. The inclusion of samples from
patients with psychosis in the context of bipolar disorder
would be particularly desirable. However, it represents a
great challenge to collect CSF from patients with acute mania
(as the patient must give informed consent and must lie still
for safe CSF collection).
A larger number of patient samples, ideally collected in
different hospital settings, and the inclusion of samples from
patients with ‘‘prodromal’’ schizophrenia (most patients with
schizophrenia present with vague mental disturbances for
months or years prior to developing overt psychosis) as well
as patients with chronic schizophrenia, would increase the
conﬁdence in the ﬁndings and would have prognostic utility.
The responsiveness of the biomarker signature to drug
treatment would also be of great interest, as this could be
used as a surrogate end point in drug-discovery studies and
could help to differentiate drug-responders from non-
responders and generally may allow for the development of
personalized treatment approaches.
The main limitation of the ﬁndings with regards to
translation into clinical practice is that, in most countries
(with the exception of Germany and some Scandinavian
countries), CSF is not routinely collected in patients with
ﬁrst-onset psychosis. A CSF-based diagnostic assay would
therefore require a sea-change in clinical practice.
The identiﬁcation of serum biomarkers would be much
more desirable, but is technically challenging. However, our
laboratory has identiﬁed a number of putative serum
biomarkers, which are currently being followed up and
validated (unpublished data).
Once sensitive and speciﬁc markers are established,
diagnostic assays can be developed to validate the identiﬁed
biomarkers on a larger sample set and, ultimately, in the
clinical setting. A likely scenario could be a multi-analyte
array conﬁguration based on up to ten indicative biomarkers.
Such systems will be conﬁgured initially into bench-top
instruments and, subsequently, into disposable, easy-to-use
diagnostic platforms for the physician’s ofﬁce or the patient’s
bedside based on hand-held readers. The sensors will be
designed with an in-built ability to allow the collected data to
be electronically transmitted directly to the physician for
interpretation.
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Biomarkers for First-Onset PsychosisEditors’ Summary
Background. Psychosis is an abnormal mental state characterized by
loss of contact with reality, often associated with hallucinations,
delusions, personality changes, and disorganized thinking. Psychotic
symptoms occur in several psychiatric disorders, including schizophrenia,
bipolar disorder, and psychotic depression. It is not clear what the
underlying biological abnormalities in the brain are, and whether they
are the same for the different psychotic illnesses. The hope is that recent
advances in brain imaging and systematic characterization of genetic
activity and protein composition in the brain might help to shed light on
mental diseases, eventually leading to better diagnosis, treatment, and
possibly even prevention.
Why Was This Study Done? This study was carried out in order to
search for biomarkers for psychosis and schizophrenia by comparing the
protein composition in the cerebrospinal fluid (the clear body fluid that
surrounds the brain and the spinal cord) of patients with different
psychotic disorders and normal individuals who served as controls.
What Did the Researchers Do and Find? The researchers used a
technique called surface-enhanced laser desorption ionization mass
spectrometry, which allows a comprehensive analysis of the protein
composition of a particular sample, on a total of 179 cerebrospinal fluid
samples. The samples came from 90 individuals without mental illness
who served as controls, 58 people with schizophrenia who were very
recently diagnosed and had not yet taken any medication, 16 patients
with depression, five patients with obsessive-compulsive disorder, and
ten patients with Alzheimer disease. All of the patients gave their
informed consent to participate in the study. The researchers found that
samples from treatment-naı ¨ve schizophrenic patients had a number of
characteristic changes compared with samples from control individuals,
and that those changes were not found in the patients with other mental
illnesses. The researchers then wanted to test whether they would see
the same pattern in a separate set of patients with schizophrenia versus
controls, which turned out to be the case. Two of the changes in the
cerebrospinal fluid that were associated with schizophrenia, namely
higher levels of parts of a protein called VGF and lower levels of a protein
called transthyretin, were also found in post-mortem brain samples of
patients with schizophrenia compared with samples from controls.
Lower levels of transthyretin were also found in serum (blood) of first-
onset drug naı ¨ve schizophrenia patients.
What Do These Findings Mean? These results suggest that this
approach has the potential to find biomarkers for psychosis and,
possibly, schizophrenia that might help in the understanding of the
molecular basis for these conditions. If shown, in future studies, to be
directly involved in causing the disease symptoms, they would be
important targets for treatment and prevention efforts, and might also
be useful for diagnostic purposes. Overall, there are promising examples,
such as this study, suggesting that new molecular techniques can yield
fresh insights into psychiatric illnesses such as schizophrenia and other
psychotic disorders. Additional studies are needed to confirm the
findings presented here and to address many open questions, and would
seem well justified given these results.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0030428.
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